VBI Vaccines Inc/BC: Nasdaq/NYSE listing notice — VBI Vaccines receives Nasdaq deficiency notice for bid price below $1.00

VBI Vaccines Inc/BC

Nasdaq letter dated Nov 1, 2023; stock closed below $1.00 for 30 consecutive business days (Sept 19 – Oct 31).
Company has 180-day compliance period until April 29, 2024 to regain minimum bid price.
Must achieve closing bid of $1.00 or more for at least 10 consecutive business days during the period.
If not cured, may be eligible for additional 180 days if it meets other listing standards and plans a reverse split.
No immediate impact on listing; shares continue trading on Nasdaq during compliance period.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

VBI Vaccines Inc/BC received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: noncompliance notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

November 1, 2023, VBI Vaccines Inc. (the “Company”) received a letter from the Listing Qualifications Department of the Nasdaq Stock Market (the “Staff”) indicating that, based upon the closing bid price of the Company’s common shares for the 30 consecutive business day period between September 19, 2023, through October 31, 2023, the Company did not meet the minimum bid price of $1.00 per share required for continued listing on The Nasdaq Capital Market (“Nasdaq”) pursuant to Nasdaq Listing Rule 5550(a)(2). The letter also indicated that the Company will be provided with a compliance period of

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001493152-23-039348

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.